NCT05653440 Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
| NCT ID | NCT05653440 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Pittsburgh |
| Condition | Aphasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-11-27 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2023-11-27 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using these naming abilities in daily life. The current research aims to evaluate novel anomia treatment approaches to improve long-term retention and generalization to everyday life. This study is one of two that are part of a larger grant. This record is for sub-study 1, which will adaptively balance effort and accuracy using speeded naming deadlines.
Eligibility Criteria
Inclusion Criteria: * Existing diagnosis of chronic (\>6 months) aphasia subsequent to left hemisphere ischemic or hemorrhagic stroke. * Impaired performance on 2/8 sections of the Comprehensive Aphasia Test. Exclusion Criteria: * History of other acquired or progressive neurological disease. * Significant language comprehension impairments * Unmanaged drug / alcohol dependence. * Severe diagnosed mood or behavioral disorders that require specialize mental health interventions.
Contact & Investigator
William Evans, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT05653440 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05653440 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05653440 currently recruiting?
Yes, NCT05653440 is actively recruiting participants. Contact the research team at ank155@pitt.edu for enrollment information.
Where is the NCT05653440 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT05653440 clinical trial?
NCT05653440 is sponsored by University of Pittsburgh. The principal investigator is William Evans, PhD at University of Pittsburgh. The trial plans to enroll 30 participants.